[1]
Hawkins T, Berman BD. Pimavanserin: A novel therapeutic option for Parkinson disease psychosis. Neurology. Clinical practice. 2017 Apr:7(2):157-162. doi: 10.1212/CPJ.0000000000000342. Epub
[PubMed PMID: 29185542]
[2]
Cummings J, Isaacson S, Mills R, Williams H, Chi-Burris K, Corbett A, Dhall R, Ballard C. Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet (London, England). 2014 Feb 8:383(9916):533-40. doi: 10.1016/S0140-6736(13)62106-6. Epub 2013 Nov 1
[PubMed PMID: 24183563]
Level 1 (high-level) evidence
[3]
Espay AJ, Guskey MT, Norton JC, Coate B, Vizcarra JA, Ballard C, Factor SA, Friedman JH, Lang AE, Larsen NJ, Andersson C, Fredericks D, Weintraub D. Pimavanserin for Parkinson's Disease psychosis: Effects stratified by baseline cognition and use of cognitive-enhancing medications. Movement disorders : official journal of the Movement Disorder Society. 2018 Nov:33(11):1769-1776. doi: 10.1002/mds.27488. Epub 2018 Nov 2
[PubMed PMID: 30387904]
[4]
Cummings J, Ballard C, Tariot P, Owen R, Foff E, Youakim J, Norton J, Stankovic S. Pimavanserin: Potential Treatment For Dementia-Related Psychosis. The journal of prevention of Alzheimer's disease. 2018:5(4):253-258. doi: 10.14283/jpad.2018.29. Epub
[PubMed PMID: 30298184]
[5]
Ballard C, Banister C, Khan Z, Cummings J, Demos G, Coate B, Youakim JM, Owen R, Stankovic S, ADP Investigators. Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer's disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study. The Lancet. Neurology. 2018 Mar:17(3):213-222. doi: 10.1016/S1474-4422(18)30039-5. Epub
[PubMed PMID: 29452684]
Level 1 (high-level) evidence
[6]
Ballard C, Youakim JM, Coate B, Stankovic S. Pimavanserin in Alzheimer's Disease Psychosis: Efficacy in Patients with More Pronounced Psychotic Symptoms. The journal of prevention of Alzheimer's disease. 2019:6(1):27-33. doi: 10.14283/jpad.2018.30. Epub
[PubMed PMID: 30569083]
[7]
Horn S, Richardson H, Xie SX, Weintraub D, Dahodwala N. Pimavanserin versus quetiapine for the treatment of psychosis in Parkinson's disease and dementia with Lewy bodies. Parkinsonism & related disorders. 2019 Dec:69():119-124. doi: 10.1016/j.parkreldis.2019.11.009. Epub 2019 Nov 11
[PubMed PMID: 31751863]
[8]
Nasrallah HA, Fedora R, Morton R. Successful treatment of clozapine-nonresponsive refractory hallucinations and delusions with pimavanserin, a serotonin 5HT-2A receptor inverse agonist. Schizophrenia research. 2019 Jun:208():217-220. doi: 10.1016/j.schres.2019.02.018. Epub 2019 Mar 2
[PubMed PMID: 30837203]
[9]
Bugarski-Kirola D, Arango C, Fava M, Nasrallah H, Liu IY, Abbs B, Stankovic S. Pimavanserin for negative symptoms of schizophrenia: results from the ADVANCE phase 2 randomised, placebo-controlled trial in North America and Europe. The lancet. Psychiatry. 2022 Jan:9(1):46-58. doi: 10.1016/S2215-0366(21)00386-2. Epub 2021 Nov 30
[PubMed PMID: 34861170]
Level 1 (high-level) evidence
[10]
Crump CJ, Litteral CA, Elsayed OH, El-Mallakh RS. Pimavanserin for bipolar disorder. Bipolar disorders. 2022 Sep:24(6):697-699. doi: 10.1111/bdi.13191. Epub 2022 Feb 24
[PubMed PMID: 35167172]
[11]
Fava M, Dirks B, Freeman MP, Papakostas GI, Shelton RC, Thase ME, Trivedi MH, Liu K, Stankovic S. A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Adjunctive Pimavanserin in Patients With Major Depressive Disorder and an Inadequate Response to Therapy (CLARITY). The Journal of clinical psychiatry. 2019 Sep 24:80(6):. pii: 19m12928. doi: 10.4088/JCP.19m12928. Epub 2019 Sep 24
[PubMed PMID: 31556975]
Level 1 (high-level) evidence
[12]
Ancoli-Israel S, Vanover KE, Weiner DM, Davis RE, van Kammen DP. Pimavanserin tartrate, a 5-HT(2A) receptor inverse agonist, increases slow wave sleep as measured by polysomnography in healthy adult volunteers. Sleep medicine. 2011 Feb:12(2):134-41. doi: 10.1016/j.sleep.2010.10.004. Epub 2011 Jan 21
[PubMed PMID: 21256805]
[13]
Vanover KE, Weiner DM, Makhay M, Veinbergs I, Gardell LR, Lameh J, Del Tredici AL, Piu F, Schiffer HH, Ott TR, Burstein ES, Uldam AK, Thygesen MB, Schlienger N, Andersson CM, Son TY, Harvey SC, Powell SB, Geyer MA, Tolf BR, Brann MR, Davis RE. Pharmacological and behavioral profile of N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl) carbamide (2R,3R)-dihydroxybutanedioate (2:1) (ACP-103), a novel 5-hydroxytryptamine(2A) receptor inverse agonist. The Journal of pharmacology and experimental therapeutics. 2006 May:317(2):910-8
[PubMed PMID: 16469866]
[14]
Meltzer HY, Roth BL. Lorcaserin and pimavanserin: emerging selectivity of serotonin receptor subtype-targeted drugs. The Journal of clinical investigation. 2013 Dec:123(12):4986-91. doi: 10.1172/JCI70678. Epub 2013 Dec 2
[PubMed PMID: 24292660]
Level 3 (low-level) evidence
[15]
Patel RS, Bhela J, Tahir M, Pisati SR, Hossain S. Pimavanserin in Parkinson's Disease-induced Psychosis: A Literature Review. Cureus. 2019 Jul 28:11(7):e5257. doi: 10.7759/cureus.5257. Epub 2019 Jul 28
[PubMed PMID: 31572642]
[16]
Cruz MP. Pimavanserin (Nuplazid): A Treatment for Hallucinations and Delusions Associated With Parkinson's Disease. P & T : a peer-reviewed journal for formulary management. 2017 Jun:42(6):368-371
[PubMed PMID: 28579723]
[17]
Shah AA, Aftab A, Coverdale J. QTc prolongation with antipsychotics: is routine ECG monitoring recommended? Journal of psychiatric practice. 2014 May:20(3):196-206. doi: 10.1097/01.pra.0000450319.21859.6d. Epub
[PubMed PMID: 24847993]